An angiotensin II receptor blocker that is used to treat high blood pressure has been recalled due to a contamination that carries a potential cancer risk; with insurance companies considering precision medicine experimental, the high cost of a promising area of medicine may be out of reach for patients; instead of using a local pharmacy, employees of the state of Utah could be paid to go to Mexico to fill their prescriptions.
An angiotensin II receptor blocker (ARB) that is used to treat high blood pressure, irbesartan, has been recalled due to a contamination. According to CNN, FDA is alerting patients that the contamination carries a potential cancer risk. The recall comes after another heart medicine, valsartan, was recalled for the same reason. The drugs have been found to be tainted with a possible carcinogen that is used to make liquid rocket fuel and can be unintentionally introduced into manufacturing. All ARBs are being tested for the contamination.
Although precision medicine has shown great promise in helping patients, insurance companies view it as experimental and will cover little of the cost of care. However, precision medicine involves running expensive genomic sequencing tests, which puts this new and promising area of cancer research out of reach for many patients, reported Kaiser Health News. While Medicare will pay for genomic testing for people with advanced cancers, few private insurers cover the tests, which leaves patients footing bills worth several thousands of dollars.
Instead of using a local pharmacy, employees of the state of Utah could be paid to go to Mexico to fill their prescriptions. The Center for Biosimilars®, a sister site of The American Journal of Managed Care®, reported that the organization that provides health benefits to the state’s workers will allow members to fill 90-day supplies of certain drugs in Mexico. The payer will arrange for and cover roundtrip airfare to San Diego, California, pay for car transportation to across the border to a facility in Tijuana, Mexico, and also pay patients a reward of $500. According to a state representative, by paying a few hundred dollars for the medical tourism program, the state could save tens of thousands of dollars.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Eliminating Enhanced PTCs Would Have Cascading Economic Impacts, Report Estimates
March 6th 2025Enhanced premium tax credits (PTCs) have made marketplace health insurance more affordable, and eliminating them could have sweeping impacts on consumers and the health care industry, according to a new report.
Read More